ArticleRheumatology (Oxford, England)2026
Canakinumab dosing intervals in pediatric colchicine-resistant FMF: outcomes and predictors of successful extension in a real-world cohort.
Nergis Akay et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.